Get started
Author

Zhanet G. Grudeva-Popova

Observed names: Z Grudeva-Popova, Z. Grudeva-Popova, Z. Grudeva‐Popova, Zhanet G. GRUDEVA-POPOVA, Zhanet GRUDEVA-POPOVA, Zhanet Grudeva Popova, Zhanet Grudeva-Popova, Жанет Грудева-Попова
ORCID: 0000-0003-4698-8600
Observed ORCID: 0000-0003-4698-8600
OpenAlex ID: A5057360885
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2025 · Wojciech Jurczak, Michal Kwiatek, et al. · Journal of Clinical Oncology · 25
PDF
Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study
2021 · Moshe Y. Levy, Deepa Jagadeesh, et al. · Blood · 20
Autoimmune Phenomena in Patients with Solid Tumors
2016 · Ivanka S. Nenova, Mariana Y. Valcheva, et al. · Folia Medica · 19
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
2023 · Luděk Pour, Monika Szarejko, et al. · Haematologica · 14
PDF
Longitudinal Dynamics of Coagulation and Angiogenesis Markers in Cancer Patients During and After Chemotherapy
2021 · Elina A. Beleva, Tanya I. Deneva, et al. · Clinical and Applied Thrombosis/Hemostasis · 12
Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia
2020 · Katya Sapunarova, Vesselina Goranova-Marinova, et al. · Annals of Medicine · 12
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial
2026 · Prithviraj Bose, Haris Ali, et al. · Journal of Clinical Oncology · 8
Clinical characteristics, disease evolution and survival in patients with chronic myeloid leukemia, BCR-ABL1 (+) and T315I mutation.
2021 · Veselina Goranova-Marinova, Alexander Linev, et al. · Folia Medica · 6
PDF
Analysis of the pharmacotherapeutic effectiveness of the tyrosine kinase inhibitors therapy in patients with Chronic Myeloid Leukemia in a single hematology center in Plovdiv, Bulgaria
2023 · Veselina Goranova-Marinova, Daniela Grekova, et al. · Pharmacia · 5
Markers of activation of coagulation in cancer patients
2022 · Snezhana S. STOENCHEVA, Veselin G. POPOV, et al. · Bratislavské lekárske listy/Bratislava medical journal · 5
PDF
Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients
2025 · Wojciech Jurczak, Michal Kwiatek, et al. · Blood · 4
PDF
Biomarkers for Early Detection of Cisplatin-Induced Nephrotoxicity
2025 · Nikolay Dimov, Antoniya Yaneva, et al. · Life · 4
Analysis of the pharmacoeconomic effectiveness of the tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia in a Single Hematology Center in Plovdiv, Bulgaria
2024 · Veselina Goranova-Marinova, Daniela Grekova-Kafalova, et al. · Pharmacia · 4
PDF
Assessment of clinical utility and predictive potential of pre-chemotherapy soluble urokinase plasminogen activator receptor: Observational single center study
2022 · Elina Beleva, Snezhana Stoencheva, et al. · Biomolecules and Biomedicine · 4
Safety and Efficacy of Cd37‐targeting Naratuximab Emtansine Plus Rituximab in Diffuse Large B‐cell Lymphoma and Other Non‐hodgkin’s B‐cell Lymphomas – a Phase 2 Study
2021 · M. Y. Levy, Z. Grudeva‐Popova, et al. · Hematological Oncology · 4
Changes in the Contractile Activity and Reactivity to 5-HT of Smooth Muscles of Rats Following Total Body Irradiation with Accelerated Electrons
2019 · Xenodochidis A. Charilaos, Raina G. Ardasheva, et al. · Folia Medica · 4
PDF
A single-center study of bone mineral density in adult patients with severe hemophilia A in correlation with markers of bone metabolism
2023 · Hristina A. Ivanova, Zhanet Grudeva-Popova, et al. · Folia Medica · 3
PDF
Dynamics of VEGF-А, Аngiopoietin-2 and HIF-1α Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery
2025 · Veselin Popov, Gabriela Raycheva, et al. · Technology in Cancer Research & Treatment · 2
PDF
Evaluation of the Effect of Radiosurgery for Target and Non-Target Lesions in Patients with Brain Metastases Using RANO-BM Criteria
2024 · Veselin Popov, Gabriela Raycheva, et al. · Technology in Cancer Research & Treatment · 2
P34 Lighthouse (op-108): Melflufen Plus Daratumumab (dara) and Dexamethasone (dex) Versus Dara in Relapsed/refractory Multiple Myeloma (rrmm) Refractory to an Immunomodulatory Drug (imid) and a Proteasome Inhibitor (pi) or Had Received ≥3 Prior Lines of Therapy Including an Imid and a Pi
2023 · M Mateos, M Szarejko, et al. · HemaSphere · 1
Liquid biopsy: an innovative and reliable method for detecting not only somatic, but also germline mutations in patients with colorectal and non-small cell lung carcinoma
2023 · Nelly Miteva-Marcheva, Hristo Ivanov, et al. · Biotechnology & Biotechnological Equipment · 1
PDF
Liquid Biopsy – Possibilities for Monitoring the Therapeutic Response in Non-Small Cell Lung Cancer
2021 · Gabriela A. Raycheva, Hristo Y. Ivanov, et al. · Folia Medica · 1
PDF
MPN-388: Assessment of Prevalence and Risk Factors for Subclinical Splanchnic Thrombosis in Patients with Myelofibrosis
2021 · Elina Beleva, Hristo Ivanov, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Prognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma
2019 · V.S. Goranova-Marinova, K. Ignatova, et al. · Annals of Oncology · 1
Адренокортикален карцином, асоцииран с белодробна тромбоемболия – литературен обзор и клиничен случай
2016 · Жанет Грудева-Попова, Веселин Попов, et al. · Редки болести и лекарства сираци · 1
PDF
Works count: 37
Citation count: 163
H-index: 7
I10-index: 6
Year
Topic
Type